Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma

The development of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) is well recognised in multiple myeloma (MM). SIADH, due to either MM or Bortezomib can be hazardous as severe hyponatremia may develop if large volumes of hypotonic intravenous fluid are used as a...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Connor-Byrne, N., Glavey, S., Tudor, R., Murphy, P., Thompson, C. J., Quinn, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359864/
https://www.ncbi.nlm.nih.gov/pubmed/30733892
http://dx.doi.org/10.1186/s40164-019-0128-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359864/
https://www.ncbi.nlm.nih.gov/pubmed/30733892
http://dx.doi.org/10.1186/s40164-019-0128-y

Ejemplares similares